Pembrolizumab After Locally Ablative Therapy May Be Beneficial in Metastatic NSCLC

Share this content:
For this phase 2 study, researchers enrolled 39 patients with oligometastatic NSCLC to start pembrolizumab 200 mg every 3 weeks within 4 to 12 weeks of undergoing LAT.
For this phase 2 study, researchers enrolled 39 patients with oligometastatic NSCLC to start pembrolizumab 200 mg every 3 weeks within 4 to 12 weeks of undergoing LAT.
The following article features coverage from the IASLC 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan. Click here to read more of Cancer Therapy Advisor's conference coverage.

Pembrolizumab after locally ablative therapy (LAT; eg, surgery, stereotactic radiation) is well-tolerated and may prolong progression-free survival (PFS) among patients with oligometastatic non–small cell lung cancer (NSCLC), according to an oral abstract presented at the International Association for the Study of Lung Cancer (IASLC) 18th Annual World Conference on Lung Cancer (WCLC) in Japan.1

There is a lack of data demonstrating the efficacy of systemic therapy for patients with NSCLC after LAT. For this phase 2 study, researchers enrolled 39 patients with oligometastatic NSCLC to start pembrolizumab 200 mg every 3 weeks within 4 to 12 weeks of undergoing LAT.

The median patient age was 64 years, 90% of patients were Caucasian, and 54% were male. Ninety percent of patients in the study were current or former smokers. The most frequently observed sites of metastasis were lung, brain, and bone. Eligible patients had LAT performed at all known disease sites. The median follow-up period from the start of LAT was 16 months.

Median PFS is not yet reached, though PFS rates at 6, 12, and 18 months were 92%, 64%, and 64%, respectively. Sixteen and 5 patients were identified as at risk beyond 12 and 24 months, respectively. Eleven patients have progressed or died to date.

Median overall survival (OS) has not been reached. OS rates at 6, 12, and 18 months were 100%, 90%, and 75%, respectively.

The authors concluded that “[c]ontinued follow-up is necessary to confirm these findings.”

Read more of Cancer Therapy Advisor's coverage of the IASLC 18th World Conference on Lung Cancer (WCLC) by visiting the conference page.

Reference

  1. Bauml JM, Mick R, Ciunci C, et al. Phase II study of pembrolizumab for oligometastatic non-small cell lung cancer (NSCLC) following completion of locally ablative therapy (LAT).  Presented at: International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer; Yokohama, Japan: October 15-18, 2017. Abstract OA 17.08.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs